Ozekibart's 52% Reduction in Risk Sparks 70% Jump Amid Concerns Over Liver Safety

Bitget App

Trade smarter

Bitget

News

Markets

Ozekibart's 52% Reduction in Risk Sparks 70% Jump Amid Concerns Over Liver Safety

Bitget-RWA2025/10/24 12:32

By:Bitget-RWA

- Inhibrx Biosciences’ ozekibart showed 52% reduced disease progression risk in chondrosarcoma, driving a 70% post-market stock surge. - Combination trials in colorectal and Ewing sarcoma showed 23%–64% response rates, suggesting broader oncology potential. - Hepatotoxicity concerns led to monitoring strategies, reducing adverse events to 11.8% in ozekibart group. - Company plans 2026 BLA submission; stock surged 63% pre-market after prior 10% decline.

Shares of Inhibrx Biosciences (NASDAQ:INBX) soared by more than 70% in after-hours trading on October 23, 2025, after the company announced encouraging Phase 2 trial data for its investigational cancer therapy ozekibart (INBRX-109) in chondrosarcoma, a rare and aggressive bone malignancy that currently lacks approved systemic treatments, as reported by an

Investing.com report

. The ChonDRAgon clinical trial, which compared ozekibart as a standalone treatment to placebo, achieved its main goal by showing a statistically significant 52% decrease in the risk of disease progression or death relative to the control group. Patients administered ozekibart experienced a median progression-free survival (PFS) of 5.52 months, more than twice the 2.66 months seen in those receiving placebo. Additionally, the drug achieved a disease control rate of 54% compared to 27.5% for placebo, with consistent positive outcomes across all predefined subgroups, according to

a Tokenist article

Ozekibart’s safety profile was generally acceptable, though liver toxicity was identified as a significant issue. Early in the study, a fatal liver-related incident led to the adoption of risk mitigation strategies, including excluding patients with advanced liver dysfunction and closely monitoring liver function during the initial treatment cycles. These interventions reduced the rate of treatment-related liver side effects to 11.8% in the ozekibart group versus 4.5% in the placebo group, with most cases being mild or moderate in severity, as detailed in

a StreetInsider release

Ozekibart's 52% Reduction in Risk Sparks 70% Jump Amid Concerns Over Liver Safety image 0

In addition to chondrosarcoma,

Inhibrx

shared encouraging interim results from expansion cohorts evaluating ozekibart in combination regimens for colorectal cancer and Ewing sarcoma. Among heavily pretreated colorectal cancer patients, the combination of ozekibart with FOLFIRI chemotherapy resulted in a 23% overall response rate and a 92% disease control rate. For Ewing sarcoma, pairing ozekibart with irinotecan and temozolomide yielded a 64% overall response rate and a 92% disease control rate, as reported by Investing.com. These outcomes indicate that the therapy may have broader potential in oncology.

The company intends to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration in the second quarter of 2026, according to Investing.com. Comprehensive data from the ChonDRAgon study will be presented at the Connective Tissue Oncology Society Annual Meeting on November 14, 2025, as noted by Tokenist.

The market responded strongly to the announcement, with

INBX

shares climbing from $28.36 on October 23 to $46.30 in pre-market trading the next day—a 63.26% increase, according to Tokenist. This jump followed a 10% drop in the previous session, highlighting the volatility typical of biotech equities. Trading volume surged to 1.15 million shares, far above the average of 151,435, per Tokenist. Retail investors on platforms such as Stocktwits became "extremely bullish," with message activity rising by 985% in 24 hours, as tracked by

Stocktwits

Financially, Inhibrx has a market capitalization near $457 million and maintains strong liquidity, with a current ratio close to 5, according to

an Investing.com story

. However, the company posted a net loss of $28.65 million in the latest quarter, mainly due to substantial research and development spending, as reported by

Timothy Sykes

. Despite these losses, analysts see ozekibart as a potential revenue driver if it gains regulatory approval.

INBX shares have climbed 140% year-to-date, reflecting strong investor confidence, though some warn that commercial success will depend on overcoming regulatory challenges and proving long-term effectiveness. With no approved therapies for chondrosarcoma, ozekibart’s potential to be first to market has drawn parallels to other breakthrough drugs in specialized oncology fields, according to Stocktwits.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops

Lock your assets and earn 10%+ APR

Lock now!

- Tether projects $15B 2025 net profit (99% margin) and explores $500B valuation via Cantor Fitzgerald-led fundraising. - Dominates $316B stablecoin market with $182B USDT circulation, plans U.S. launch of regulated USAT via Anchorage Digital. - Faces transparency scrutiny despite $127B Treasury reserves and $41M CFTC fines, lacks Big Four audit for reserves. - Expands into AI, energy, and tokenized assets via Plasma blockchain, aiming tech conglomerate transformation. - Balancing U.S. GENIUS Act complianc

Bitget-RWA•2025/10/25 00:42

Bitcoin News Update: Early Bitcoin Holders Transfer $16.6 Million to Counter Quantum Computing Risks

- A 14-year-old Bitcoin wallet (18eY9o) moved $16.6M in a single transaction, reigniting concerns over quantum computing threats to legacy P2PK addresses. - Experts warn quantum machines could crack Bitcoin's encryption within 4-5 years, with 25% of Bitcoin ($554B) at risk, particularly older wallets. - Companies like SEALSQ and Xanadu are advancing post-quantum solutions, but analysts stress urgent action is needed by 2026 to secure crypto infrastructure. - Institutional adoption of custodial products and

Bitget-RWA•2025/10/25 00:42

Bitcoin News Update: Early Bitcoin Holders Transfer $16.6 Million to Counter Quantum Computing Risks

AAVE Declines by 0.48% as Acquisition and DeFi Growth Unfold

- Aave (AAVE) fell 0.48% to $227.84 on Oct 24, 2025, amid mixed investor sentiment from strategic moves and market dynamics. - Aave Labs acquired Stable Finance to expand institutional-grade credit tools and integrate onchain savings platforms for retail users. - The acquisition adds Mario Baxter Cabrera as product director and aligns with Aave's shift toward structured credit instruments and diversified collateral. - Technical indicators show short-term consolidation, with 30-day and annual trends indicat

Bitget-RWA•2025/10/25 00:42

Dogecoin News Today: Dogecoin's Foray into Football Seeks to Drive Practical Use Despite Ongoing Price Challenges

- Dogecoin (DOGE) faces bearish pressure near $0.20 resistance, with sellers dominating amid failed breakouts and macroeconomic headwinds. - Technical indicators signal oversold conditions, while $0.194–$0.196 support zone could trigger rebounds or deeper corrections. - House of Doge's acquisition of Italian football club Triestina aims to boost real-world adoption via DOGE payments for tickets and merchandise. - Market remains divided: $0.20 retest could reignite bullish momentum, while breakdown below $0

Bitget-RWA•2025/10/25 00:22